Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit

by @JTC_PALIdev | Nov 14, 2024 | Press Releases

Presentation to highlight advances in fibrostenotic Crohn’s Disease and the potential of localized PDE4 inhibition Carlsbad, CA, Nov. 14, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the...

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

by @JTC_PALIdev | Nov 12, 2024 | Press Releases

Commenced enrollment and dosing in Phase 1 clinical study of PALI-2108 for the treatment of moderate-to-severe Ulcerative Colitis (UC) Carlsbad, CA, Nov. 12, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the...

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

by @JTC_PALIdev | Nov 7, 2024 | Press Releases

Carlsbad, CA, Nov. 07, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with...

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

by @JTC_PALIdev | Oct 31, 2024 | Press Releases

Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD) PALI-2108 demonstrates in ex vivo studies; targeted activation and reduced side effects, potentially enhancing patient compliance compared to existing PDE4 inhibitors...

Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology’s (ACG) 2024 Annual Scientific Meeting

by @JTC_PALIdev | Oct 15, 2024 | Press Releases

Carlsbad, CA, Oct. 15, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with...